Endogenous Anti-HER2 Antibodies Block HER2 Phosphorylation and Signaling through Extracellular Signal-Regulated Kinase

R. Bruce Montgomery, Ekram Makary, Kathy Schiffman, Vivian Goodell, and Mary L. Disis

Abstract

Immunologic targeting of the oncoprotein HER2/neu with monoclonal antibodies is an important component of current therapeutic strategies for patients with locally and systemically advanced breast cancer. Engineered antibodies targeting HER2 may have agonist or antagonist effects on HER2, but little is known about whether endogenous antibodies modulate HER2 activity. Vaccination of patients with HER2 peptides successfully induced antibodies in a minority of patients with HER2-expressing malignancy. A subset of antibodies specifically suppressed phosphorylation of HER2 on tyrosine Y1248, a residue critical for HER2 signaling through extracellular signal-regulated kinase. These antibodies also suppressed extracellular signal-regulated kinase phosphorylation and inhibited colony formation in soft agar. The majority of the antibodies that suppressed HER2 phosphorylation displayed specificity for amino acids 328 to 343 and 369 to 384. The isotype of anti-HER2 antibodies was predominantly IgG3 of low avidity, suggesting a Th1 response to peptide vaccine. Endogenous anti-HER2 antibodies can effectively suppress HER2 kinase activity and downstream signaling to inhibit the transformed phenotype of HER2-expressing tumor cells. (Cancer Res 2005; 65(2): 650-6)

Introduction

The oncoprotein HER2/neu is overexpressed in many epithelial malignancies and is an established target for antibody and vaccine therapies. HER2 is constitutively activated in the absence of ligand and signaling occurs through phosphorylation of specific tyrosine residues which serve as docking sites for the adaptor molecules SHC and GRB2 with subsequent activation of Ras-ERK and PI-3K pathways (1–3). HER2 activation of the extracellular signal-regulated kinase (ERK) pathway is primarily dependent on phosphorylation of Y1248/1253 in the intracellular domain of HER2 and mutation of this residue substantially diminishes the transforming potential of HER2 (1). Targeting of HER2 with monoclonal antibodies is one means of suppressing HER2-induced transformation and these antibodies mediate an array of effects on tumor growth and signal transduction. These include antibody-dependent cell-mediated cytotoxicity, down-regulation of cell surface HER2, inhibition of receptor heterodimerization of HER2 with other epidermal growth factor receptor family members, and suppression of cell cycle progression by induction of p27Kip1 (4–8). A number of groups have shown that patients with HER2-expressing malignancies develop endogenous antibodies to HER2 (9–11). Little is known about the effects of these endogenous antibodies on phosphorylation of HER2 and its downstream signaling. We explored the effects of antibodies induced by HER2 peptide vaccines on HER2 phosphorylation, signaling through the ERK/mitogen-activated protein kinase pathway and proliferation of HER2-expressing breast cancer cell lines.

Materials and Methods

Patient Samples. Patients with HER2-positive stage III or IV breast or ovarian cancer were eligible for a phase I Institutional Review Board–approved study of HER2 peptide–based vaccine. Forty-five patients received one of three vaccines: (1) ECD vaccine containing peptides p42-56, p98-114, and p328-345; (2) ICD vaccine containing peptides p776-793, p927-941, and p1166-1180; or (3) HLA-A2 vaccine, containing peptides p369-384, p688-703, and p971-984. Vaccines were given as previously described (12).

ELISA. Capture ELISA for protein-specific responses was done as previously reported using an IgG-specific secondary antibody (11). Peptide-specific responses were assessed using 96-well Immulon 4 plates (Dynatech Laboratories, Chantilly VA) incubated overnight at 4°C with HER2 peptides at a concentration of 10 μg per well. Wells were blocked with PBS and 1% bovine serum albumin, 100 μL per well for 4 hours at room temperature. The wells were incubated with patient sera diluted 1:100 and 1:200 for 1 hour at room temperature. Goat anti-human IgG was added to the wells at a 1:5,000 dilution in PBS/1% bovine serum albumin and incubated for 45 minutes at room temperature. TMB developing reagent is added and the reaction stopped with 1 N HCl and the absorbance read at 450 nm. Antibody levels were quantitated by comparison to a standard curve. Positive HER2 protein or peptide-specific antibody levels were defined as previously described (13).

Flow Cytometry. HER2-expressing, SK-BR-3 breast cancer cells, and a HER2-negative MCF-7 subline were incubated with patient sera at 1:20 dilution at saturating concentrations followed by FITC-conjugated goat antihuman F(ab′)2 serum (Pierce, Rockford, IL). Each incubation was done for 60 minutes at 4°C. After the final wash, cells were fixed with 2% formaldehyde-PBS, Cells were analyzed by flow cytometry with a FACSCalibur instrument system (Becton Dickinson, San Jose, CA).

Antibody Isolation. Serum from patients with HER2-specific antibodies as defined by ELISA was separated by fast protein liquid chromatography over Protein-G Sepharose (Amersham, Sunnyvale, CA). Fractions were brought to pH 7.4, checked for purity by silver stain, concentrated, and assayed for protein concentration.

Western Analysis. Antibodies were to phosphotyrosine (4G10, Upstate Biotechnology, Lake Placid, NY) phosphoHER2 (Cell Signaling, Mountain View, CA), HER2 7.16.4 (Ab-4, Oncogene Sciences, Cambridge, MA), HER2 TA-1 (Ab-5 Oncogene Sciences), ERK and phosphoERK (Cell Signaling), and to tyrosine phosphorylated residues of HER2 (Ab 2247, 2249, 2241, Cell Signaling). The phospho-HER2 site–specific antibodies utilized in this study were generated against peptides phosphorylated on the residues corresponding to Y1248, Y1221, and Y877. Antibodies undergoing negative and positive selection, bind specifically to phosphorylated HER2, and do not bind to unphosphorylated peptide. Thirty micrograms of protein were loaded into an 8% to 16% gel, run, and transferred to nitrocellulose. The membranes were blocked overnight at 4°C in 5% milk/PBS. Antibodies were added at a 1:1,000 dilution for 1 hour in 3% bovine serum albumin/PBS. Anti-mouse horseradish peroxidase-linked antibody was added, and visualization was performed with enhanced chemiluminescence (Amersham, Piscataway, NJ).
peroxidase antibody (Pierce) was added at 1:2,000 dilution for 30 minutes. Signal was detected with enhanced chemiluminescence Plus (Amersham).

Colony Assays. SK-BR-3 were exposed to indicated antibodies for 4 hours at 10 μg/mL, trypsinized, and plated at 10,000 cells per well in 6-well plates in 1% agarose. Colonies larger than 60 μm were counted at 14 days. Data points represent average ± SD for triplicate wells. All assays were done thrice.

Evaluation of Anti-HER2 Antibody Avidity and Isotype. HER2-specific antibody levels were quantitated and avidity and isotype specificity was evaluated as previously described (14, 15). Two-fold serial dilutions of serum samples were plated in duplicate and incubated for 3 hours at room temperature. After four washes, 200 μL of wash buffer containing 8 mol/L urea was added to one of the duplicate wells and incubated at room temperature for 3 minutes. All wells were washed four times. For the detection of antibody binding the plates, goat anti-human IgG1, IgG2a, IgG3, and IgG4 conjugated with horseradish peroxidase (diluted 1:10,000; Zymed Laboratories, South San Francisco, CA) was added for 45 minutes at room temperature. After washing, 3,3′,5,5′ -tetramethylbenzidine substrate solution (Kirkegaard & Perry Laboratories, Gaithersburg, MD) was added, and the reaction was allowed to proceed for 3 to 5 minutes and was stopped by adding 75 μL of 1 N HCl per well. For a given patient serum dilution, the avidity index was calculated using the following formula: (change of OD with urea/change of OD without urea) × 100; and the avidity index was expressed as a percentage. An avidity index <30% is considered low avidity, 31% to 50% is considered intermediate avidity, and >51% is considered high avidity. Avidity is reported here at the 1:25 dilution of sera.

Results

Endogenous HER2-Specific Antibodies Bind Cell Surface HER2. Eleven patients entered on HER2 peptide vaccine studies developed antibodies with specificity to the HER2 protein during the course of vaccination as defined in Materials and Methods. To determine if peptide-induced antibodies could effectively recognize native HER2, we assayed the binding of antibodies to cell surface HER2. The HER2-positive breast cancer cell line SK-BR-3 was utilized as the positive control target and a clone of MCF-7 with low HER2 expression was used as the negative control target. Serum from patients and controls without detectable anti-HER2 antibodies was used as negative control samples. Analysis of representative samples is shown in Fig. 1. Antibodies from all patients were able to bind HER2 in its native conformation on the cell surface (Fig. 1A) and did not bind to the HER2 negative control cells (Fig. 1B). Essentially, all positive patient sera bound with the intermediate fluorescence shown in Fig. 1A.

The Effect of HER2-Specific Antibodies on HER2 and ERK Phosphorylation. One mechanism by which antibodies might inhibit cell proliferation and transformation is by blocking activation of HER2 at the cell surface, thereby suppressing effective downstream signal transduction. Antibodies from serum samples collected prior to vaccination and at the completion of the vaccination course were purified by fast protein liquid chromatography and incubated with SK-BR-3, a HER2-expressing human breast cancer cell line for 1 hour and whole protein lysates analyzed for HER2 phosphorylation on residues 877, 1221, and 1248. Antibodies obtained from postvaccination serum from 6 of 11 patients suppressed Y1248 phosphorylation specifically (Fig. 2A). One patient’s serum contained antibodies which suppressed HER2 phosphorylation prior to vaccination and antibodies isolated after vaccination were able to further suppress Y1248 phosphorylation (sample 4). Phosphorylation of phosphoepitides Y877 and Y1221 was unaffected by antibodies or by exposure to the control antibody c-neu 5 which up-regulates HER2 phosphorylation.

Figure 1. Endogenous anti-HER2 antibodies bind native, cell surface HER2. A. HER2-positive SK-BR-3 cells were incubated with c-neu 5 monoclonal antibody to HER2 (shaded), sera from a patient vaccinated with HER2 peptide (dashed line), or control sera (solid line) and antibodies detected with FITC-labeled secondary antibody. B. HER2-negative MCF-7 breast cancer cells were incubated with control sera without HER2 antibodies (solid line) and patient sera containing anti-HER2 antibodies (dashed line).

The Y1248 phosphoresidue regulates association of SHC with HER2 and mutation or deletion of Y1248 abrogates downstream ERK activation (1). For this reason, we then assessed the effects of these antibodies on ERK activation in the same lysates and showed that four of these patients had antibodies induced by vaccination which suppressed ERK activation without suppressing total cellular ERK levels (Fig. 2A).

Time Course of HER2 Antibody Effects on HER2 and ERK Phosphorylation. To better delineate the effect of these antibodies on HER2 activation, the effects of suppressive antibodies were further characterized. Incubation with antibodies from patients 1 and 2 suppressed HER2 phosphorylation maximally by 60 to 120 minutes with a return to baseline after 6 hours (Fig. 2B). These antibodies also suppressed ERK phosphorylation by 60 to 120 minutes and suppression was maintained for at least 24 hours. Because HER2 transformation may also be mediated by activation of the PI-3K pathway, we probed the same lysates with antibodies to phosphorylated AKT, but there were no changes in phosphoAKT levels over the same time interval (data not shown).

Effect of Induced Antibodies on Colony Formation. The effect of antibodies on anchorage-independent growth in semisolid agar, a standard assay for the transformed phenotype, was tested from a select number of samples for which adequate amounts of paired antibodies were available. Three of the
antibodies, which suppressed both HER2 phosphorylation and ERK activation (samples 1, 2, and 7), were tested in parallel with antibodies from patients whose antibodies suppressed ERK phosphorylation without affecting HER2 (sample 3) or had no effect on phosphorylation of either HER2 or ERK (samples 6 and 10). The antibody 7.16.4 (c-neu 5), a known inhibitor of HER2 mediated transformation, suppressed colony formation of SK-BR-3 to 40% of vehicle treated control. The induced antibodies, which showed inhibition of both HER2 and ERK phosphorylation, effectively blocked colony formation to between 30% and 60% of control (Fig. 3), whereas antibodies from prevaccination sera showed no effect. Antibodies purified from a control patient

A.

<table>
<thead>
<tr>
<th>Pt ID</th>
<th>C-neu 5</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaccine</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
</tbody>
</table>

\[ \alpha \text{HER2 (Y1248)} \]

\[ \alpha \text{HER2 (Y877)} \]

\[ \alpha \text{HER2 (Y1221)} \]

\[ \alpha \text{HER2} \]

\[ \alpha \text{ERK} \]

\[ \alpha \text{ERK} \]

B.

1

<table>
<thead>
<tr>
<th>Normal control</th>
<th>Ab 15 min</th>
<th>Ab 60 min</th>
<th>Ab 120 min</th>
<th>Ab 6 hrs</th>
<th>Ab 12 hrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>[ \alpha \text{HER2 (Y1248)} ]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[ \alpha \text{HER2 (Y877)} ]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[ \alpha \text{HER2} ]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2

<table>
<thead>
<tr>
<th>Normal control</th>
<th>Ab 15 min</th>
<th>Ab 60 min</th>
<th>Ab 120 min</th>
<th>Ab 6 hrs</th>
<th>Ab 12 hrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>[ \alpha \text{ERK} ]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>[ \alpha \text{ERK} ]</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 2. Effects of induced anti-HER2 antibodies on HER2 and ERK phosphorylation. Patient sera were procured before (−) and after (+) HER2 peptide vaccination. Antibodies were purified over by Protein A chromatography and used to treat HER2-expressing SK-BR-3 breast carcinoma cells in culture. Control and patient antibodies were used at 10 μg/mL for 1 hour (A) or antibodies from patients 1 and 2 for indicated periods (B) and protein from lysates analysed by Western with antibodies specific for tyrosine phosphorylation on residues 877, 1221, and 1248 (pHER2) and for total HER2 levels. The same samples were run in tandem and probed with antibodies to phosphorylated ERK (pERK) or total ERK.
also had no significant effect on the number of colonies. The clear difference in effect on growth in semisolid agar between prevaccination and postvaccination antibodies show that the ability to suppress HER2 phosphorylation is capable of modulating downstream signaling and phenotypic transformation, which is dependent on HER2 function.

**Specificity of Induced Anti-HER2 Antibodies.** The specificity of antibodies induced by HER2 peptide vaccination was tested against the panel of vaccine peptides to determine if suppression of phosphorylation and ERK signaling was associated with generation of immunity to a domain of HER2 used in the vaccine. All of the antibodies, which suppressed ERK phosphorylation, reacted with peptides containing amino acids 328 to 345 or 369 to 384 (Table 1). Patient sera often contained antibodies with specificity to other peptides spanning the extracellular or intracellular domain (amino acids 1-652) or intracellular domain (amino acids 682-1255), although there was no association with inhibition of HER2 phosphorylation or ERK with antibodies to the other domains of HER2.

**Isotype and Avidity of Induced Anti-HER2 Antibodies.** This peptide based vaccine strategy using granulocyte macrophage colony-stimulating factor as adjuvant induces T-cell responses in >90% of patients completing vaccination (12). Although this strategy was not specifically designed to induce antibodies, characterizing the immunoglobulin isotypes induced by the vaccine and the level of induction of each isotype may help to both define Th1 versus Th2 help induced by this approach, as well as to direct subsequent approaches to generating HER2 antibodies. We evaluated the isotype class of IgG antibodies induced in these patients and characterized avidity for the bulk antibody as previously described (14, 15). Some samples could not be adequately analyzed due to insufficient amounts of serum (samples 7 and 10). As shown in Table 2, high levels of HER2-specific IgG can be achieved in a subset of patients, with HER2-specific IgG ranging from 1.2 up to 9 μg/mL. Most of the responses were of the IgG3 isotype and were of low avidity, suggesting induction of a Th1 response, and consistent with the effective induction of T-cell help. The samples with the highest levels of HER2-specific IgG had the greatest effect on HER2 phosphorylation (Table 2; samples 1, 2, 3, 7, and 9).

**Discussion**

The induction of target-specific antibodies is an important component of successful vaccine strategies. The generation of effective antitumor immunity to HER2-expressing malignancies requires HER2-specific antibodies and CTLs to completely block tumor formation in some models and significantly improves vaccination efficacy in others (16, 17). In some models, induction of antibodies alone is sufficient for protection from implantation with HER2-expressing tumors and rejection of established tumors (18). The studies reported here show that vaccination in patients induces antibodies which suppress HER2 phosphorylation and downstream activation of ERK. ERK is crucial to HER2-mediated transformation, and although a number of oncoproteins can transform mammary epithelium in animal models, HER2 specifically activates the ERK/mitogen-activated protein kinase pathway, and relies on this pathway to mediate transformation (19). Inhibitors of mitogen-activated protein kinase kinase, the upstream activator of ERK, block phenotypic transformation by HER2 in the same model, confirming the importance in ERK signaling for transformation (19). Other pathways, which are implicated in HER2 mediated transformation, also depend on ERK activity, such as induction of cyclin D and p21Cip1 (20, 21). Although other signal transduction pathways are clearly important in HER2-mediated transformation, activation of ERK is a consistent downstream consequence of HER2 expression and is generally considered the principal driver of cell proliferation (22). The ability of these antibodies to suppress ERK activity has other implications as well, because suppression of ERK in HER2-expressing cells restores sensitivity to tamoxifen (23). This seems to be related to the ability of HER2 activation of ERK to suppress estrogen receptor function and ERK inhibition to restore estrogen receptor expression (24). Agonistic antibodies, which activate HER2 phosphorylation, stimulate ERK activity and increase measures of transformation in vitro (25, 26).

In this study, we found that the ability of vaccine-induced antibodies to inhibit HER2 phosphorylation correlated well with suppression of downstream ERK activity and subsequent suppression of proliferation. However, antibodies isolated from two samples suppressed HER2 phosphorylation with limited effect on ERK activation, and antibodies from one sample partially suppressed

---

**Figure 3.** Effects of induced anti-HER2 antibodies on colony formation. HER2-expressing SK-BR-3 breast carcinoma cells were treated with antibodies from prevaccination and postvaccination serum for 4 hours at 10 μg/mL, trypsinized and plated at 10,000 cells per well in 6-well plates in 1% agarose containing antibody at 10 μg/mL. Colonies larger than 60 μm were counted at 14 days. Columns, average for triplicate wells; bars, ± SD. All assays were done thrice.
ERK activity without having any effect on cell proliferation (Fig. 2A). Monoclonal antibodies may suppress HER2-mediated proliferation in vitro through inhibition of dimerization, down-regulation of cell surface HER2 (leading to reduced signaling), by inhibiting interactions with downstream signaling molecules such as SHC or GRB2 or by changing the conformation of homodimers or heterodimers within the cell membrane. If HER2 phosphorylation is suppressed without suppressing dimerization with HER3, generally considered the most active heterodimer with regard to proliferation (27), signaling may continue. Antibodies with different epitopes could potentially change the orientation of HER2 homodimers or heterodimers to one another, substantially changing phosphorylation and downstream signaling. As proposed by Yip et al. (25), antibodies to HER2 are predicted to change the rotational conformation of dimers relative to one another and in this way either inhibit or activate HER2 signaling. If antibodies suppress intramolecular phosphorylation without down-regulating membrane localization, effective suppression of ERK signaling may not occur. Suppression of ERK may require that a threshold be reached to adequately suppress anchorage independent growth (sample 4), accounting for the lack of effect for this single sample. Despite these caveats, the ability of endogenous antibodies to suppress ERK signaling is an important and relevant mechanism for inhibition of cell proliferation.

Herceptin (trastuzumab) is a humanized monoclonal IgG1 antibody, which binds to amino acids 529 to 625 in the juxtamembrane region of HER2. In preclinical models, trough levels of 20 μg/mL are the minimum necessary for efficacy and levels in patients

<table>
<thead>
<tr>
<th>Sample</th>
<th>HER2 amino acid peptide sequence</th>
<th>HER2 IgG levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>42-56 98-114 328-345 369-384 688-703 776-790 927-941 971-984 1166-1180</td>
<td>9.26</td>
</tr>
<tr>
<td>2</td>
<td>++ + + + + + + + +</td>
<td>4.11</td>
</tr>
<tr>
<td>3</td>
<td>++ + + + + + + +</td>
<td>8.40</td>
</tr>
<tr>
<td>4</td>
<td>++ + + + + + + +</td>
<td>1.81</td>
</tr>
<tr>
<td>5</td>
<td>++ + + + + + + +</td>
<td>1.90</td>
</tr>
<tr>
<td>6</td>
<td>++ + + + + + + +</td>
<td>8.00</td>
</tr>
<tr>
<td>7</td>
<td>++ + + + + + + +</td>
<td>2.00</td>
</tr>
<tr>
<td>8</td>
<td>++ + + + + + + +</td>
<td>1.54</td>
</tr>
<tr>
<td>9</td>
<td>++ + + + + + + +</td>
<td>2.50</td>
</tr>
<tr>
<td>10</td>
<td>++ + + + + + + +</td>
<td>1.20</td>
</tr>
<tr>
<td>11</td>
<td>++ + + + + + + +</td>
<td>1.20</td>
</tr>
</tbody>
</table>

NOTE: Specificity for serum antibodies from patients with documented anti-HER2 responses to ELISA was determined, and a positive response was determined as defined in Materials and Methods.

<table>
<thead>
<tr>
<th>Sample</th>
<th>HER2 lgG levels</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>9.26</td>
</tr>
<tr>
<td>2</td>
<td>4.41</td>
</tr>
<tr>
<td>3</td>
<td>8.40</td>
</tr>
<tr>
<td>4</td>
<td>1.81</td>
</tr>
<tr>
<td>5</td>
<td>1.90</td>
</tr>
<tr>
<td>6</td>
<td>8.00</td>
</tr>
<tr>
<td>7</td>
<td>2.00</td>
</tr>
<tr>
<td>8</td>
<td>1.54</td>
</tr>
<tr>
<td>9</td>
<td>2.50</td>
</tr>
<tr>
<td>10</td>
<td>1.20</td>
</tr>
<tr>
<td>11</td>
<td>1.20</td>
</tr>
</tbody>
</table>

NOTE: Levels of antibody, avidity, and isotype of serum antibodies from patients with anti-HER2 responses was determined as defined in Materials and Methods. Inadequate amounts of serum were available to fully characterize some samples.
receiving weekly therapy average 70 μg/mL (28). In vitro, hereceptin induces minimal effects on HER2 phosphorylation when analysis is carried out under denaturing conditions (29). Herceptin down-regulates membrane-associated HER2 with subsequent suppression of ERK, ultimately resulting in cell cycle arrest (30, 31). In vivo it seems that antibody dependent cellular cytotoxicity plays a significant role in herceptin’s inhibitory effects on HER2 expressing cells, as in transgenic animals lacking Fc receptors efficacy is reduced by ~60% (4). The antibodies described in this study were principally of the IgG3 isotype and were able to achieve rapid suppression of HER2 phosphorylation and ERK activation within 15 minutes using concentrations of 10 μg/mL, which are comparable to serum levels of herceptin used in clinical practice. Antibodies induced by vaccination differ substantially in their effect on HER2 phosphorylation, suggesting significant differences in mechanism of effect.

The antibodies which suppressed HER2 phosphorylation specifically bind to peptides incorporating amino acids 328 to 345 or 369 to 384, portions of the extracellular domain predicted to induce T helper activity. Other investigators have shown that in animal models, peptides targeting amino acids 316 to 339 and 378 to 398 of HER2 effectively induced antibodies which blocked proliferation and metastasis of HER2-expressing cell lines (32, 33). These domains are in close proximity or overlap with the peptide specificity of the endogenous antibodies characterized in this study, suggesting that this region of the extracellular domain is a particularly important region of HER2 to consider in vaccines targeting humoral immunity to HER2. Monoclonal antibodies raised to different portions of HER2 may have inhibitory or activating effects and this has raised the specter that induction of HER2 effectively induced antibodies which blocked proliferation and metastasis of HER2-expressing cell lines (32, 33). These domains are in close proximity or overlap with the peptide specificity of the endogenous antibodies characterized in this study, suggesting that this region of the extracellular domain is a particularly important region of HER2 to consider in vaccines targeting humoral immunity to HER2. Monoclonal antibodies raised to different portions of HER2 may have inhibitory or activating effects and this has raised the specter that induction of antibodies in vivo might even be harmful by stimulating proliferation in target cells in which HER2 kinase activity is activated (26). We did not find any evidence of HER2 activation by these antibodies, nor have we found HER2 stimulatory activity in a limited number of HER2-specific antibodies isolated from patients with HER2-expressing malignancies (data not shown). The antibodies identified in this study showed affinity to a number of epitopes on HER2, but essentially all bound to the extracellular domain peptides spanning amino acids 328 to 384. Epitopes derived from this region of HER2 have been used by a number of investigators to induce highly effective antibodies to HER2 in animal models. Jasinska et al. (33) used peptides spanning putative B cell epitopes of human HER2 to immunize mice against the human HER2 protein. Of seven peptides, the most immunogenic peptide encompassed amino acids 378 to 398, and antibodies to this peptide effectively suppressed HER2-positive tumor proliferation. Of interest is their finding that the antibodies can mediate complement- and antibody-dependent cell lysis, as well as proliferation suggesting that antibodies to this region might mediate suppressive effects through multiple mechanisms in vivo. Dakappagari et al. tested a variety of predicted B cell epitopes from the Neu/ErbB-2 receptor and enabled coupling to the MAP kinase pathway. EMBO J 1994;13:3302–11.

5. Yakes FM, Chirntratanaloh W, Ritter CA, King W.


Endogenous Anti-HER2 Antibodies Block HER2 Phosphorylation and Signaling through Extracellular Signal-Regulated Kinase

R. Bruce Montgomery, Ekram Makary, Kathy Schiffman, et al.


Updated version  Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/65/2/650

Cited articles  This article cites 34 articles, 21 of which you can access for free at:
http://cancerres.aacrjournals.org/content/65/2/650.full.html#ref-list-1

Citing articles  This article has been cited by 9 HighWire-hosted articles. Access the articles at:
/content/65/2/650.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.